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Mas in the injured artery were greater, with less neointimal formation than in wild-type (WT) mice, and that increases in ACE2 expression and neointimal formation in the injured artery were also observed with treatment with an AT 1 receptor blocker (ARB), olmesartan, suggesting that AT 1 receptor blockade by ARBs seemed to alter the balance between the ACE2/Ang-(1-7)/Mas axis and the ACE/Ang II/AT 1 receptor axis to improve vascular remodeling. 9 Ang II type 2 (AT 2 ) receptor stimulation is known to be involved in the beneficial effects of ARBs on cardiovascular remodeling. In addition to cross talk between the AT 1 receptor and Mas, the role of the AT 2 receptor in terms of the effects mediated by the ACE2/Ang-(1-7)/Mas pathway, distinguishing the Mas and AT 2 receptor signaling pathways, has been highlighted. 10 Previously, it was reported that Ang-(1-7) exerts a role as a vasodepressor via AT 2 receptor activation in the presence of partial AT 1 receptor blockade 11 and that the vasoprotective and atheroprotective effects of Ang-(1-7) are mediated by restoration of nitric oxide bioavailability via both the Mas and AT 2 receptors. 4 It is reported that AT 2 receptor expression in the femoral artery was increased after cuff placement. 12 These results led us to examine the possibility that the Ang-(1-7)/AT 2 receptor pathway is involved in the inhibitory effects of ARB on vascular remodeling using Mas-knockout (MasKO) mice and AT 2 receptor knockout (AT 2 KO) mice.
Methods
This study was performed in accordance with the National Institutes of Health guidelines for the use of experimental animals. The experimental protocol was approved by the Animal Studies Committee of Ehime University.
Animals and Treatment
AT 2 KO (C57BL/6J background) 13 mice and MasKO mice (C57BL/6J background) aged 10 to 11 weeks, weighing 25 to 30 g, were used. WT (C57BL/6J) mice were used as control. Animal treatment and targeted disruption of the Mas gene are presented in Methods in the online-only Data Supplement.
Morphometric Analysis and Immunohistochemical Staining
The femoral arteries were taken 14 days after cuff placement and fixed with 10% neutral-buffered formalin. Paraffin-embedded cross-sections were prepared as described previously. 12 Samples were examined with a Zeiss Axioskop 2 microscope (Carl Zeiss, Oberkochen, Germany) equipped with a computer-based imaging system.
14
Dihydroethidium Staining
Superoxide generation in cryostat frozen section was evaluated using fluorogenic dihydroethidium (5 μmol/L), as described previously. 15 The intensity of fluorescence was analyzed and quantified using computer imaging software (Densitograph, ATTO Corp).
Quantitative Real-Time Polymerase Chain Reaction
Please see the online-only Data Supplement.
Statistical Analysis
All values are expressed as mean±SD in the text and figures. Data were evaluated by ANOVA. If a statistically significant effect was found, post hoc analysis was performed to detect the difference between the groups. Values of P<0.05 were considered to be statistically significant. To explore the involvement of the ACE2/Ang-(1-7)/Mas axis in vascular remodeling, we used a vascular injury model induced by polyethylene-cuff placement around the femoral artery in WT and MasKO mice. As shown in Figure 1A and Figure S1 in the online-only Data Supplement, the neointimal area 14 days after cuff placement was significantly larger in MasKO mice compared with WT mice. Proliferating cell nuclear antigen labeling index was also higher in both the intima and media in MasKO mice ( Figure 1B ; Figure S2 ). We examined the possibility that the inhibitory effect of ARB on vascular injury would involve activation of the ACE2/Ang-(1-7)/Mas axis. Figure S3 shows the dose-dependent effect of azilsartan on neointimal formation. We used a nonhypotensive dose of azilsartan (0.3 mg/kg per day) in the following experiments. We compared the effect of azilsartan on neointimal formation between WT and MasKO mice and observed that treatment with azilsartan decreased neointimal area in the injured artery more markedly in control WT mice than in MasKO mice (76.1% reduction in WT mice, 64.3% reduction in MasKO mice; Figure 1A ; Figure  S1 ). Basal levels of proliferating cell nuclear antigen labeling index, mRNA levels of monocyte chemoattractant protein-1, tumor necrosis factor-α (TNF-α ), and interleukin-1β (IL-1β), and superoxide anion production before cuff placement did not differ between WT and MasKO mice (data not shown). The inhibitory effect of azilsartan on proliferating cell nuclear antigen labeling index was also more marked in WT mice than in MasKO mice ( Figure 1B ; Figure S2 ). The mRNA levels of monocyte chemoattractant protein-1, TNF-α, and IL-1β in the injured artery determined 7 days after cuff placement were more markedly increased in MasKO mice. Treatment with azilsartan attenuated the increases in mRNA levels of these cytokines; however, these inhibitory effects of azilsartan were less marked in MasKO mice (Figure 2 ). To assess the involvement of oxidative stress in the attenuation of neointimal formation in azilsartan-and Ang-(1-7)-treated WT and MasKO mice, the production of superoxide anion in the intima and media of injured arteries was evaluated by dihydroethidium staining (Figure 3 ; Figure S4 ). Superoxide anion production in the intima and media 7 days after cuff placement was significantly greater in MasKO mice than in WT mice. Treatment with azilsartan and Ang-(1-7) decreased superoxide anion production in the injured artery in WT mice. These inhibitory effects of azilsartan and Ang-(1-7) were less marked in MasKO mice. Next, we assessed the expressions of mRNA of oxidative stress markers including NAD(P)H (nicotinamide adenine dinucleotide phosphate) oxidase subunits, p22phox, p40phox, p47phox, p67phox, gp91phox, Nox1, Nox4, and Rac1 ( Figure S5 ). We observed that mRNA expressions of p22phox and gp91phox were higher in MasKO mice and that treatment with azilsartan or Ang-(1-7) significantly decreased mRNA expressions of p22phox, p40phox, p47phox, p67phox, gp91phox, Nox1, and Rac1, whereas these effects of azilsartan or Ang-(1-7) were Ohshima et al ACE2/Ang-(1-7)/AT 2 Axis in Vascular Remodeling e55 less in MasKO mice ( Figure S5 ). Administration of Ang-(1-7) at a nonhypotensive dose decreased neointimal formation, proliferating cell nuclear antigen labeling index, expression of mRNA of monocyte chemoattractant protein-1, TNF-α, and IL-1β, and superoxide anion production in the injured artery, and these effects of Ang-(1-7) were more marked in MasKO mice than in control WT mice ( Figures 1A, 1B , 2, and 3).
Results
Effect of Administration of Azilsartan or
Effect of Administration of Azilsartan or Ang-(1-7) on mRNA Levels of ACE, ACE2, Mas, AT 1 Receptor, and AT 2 Receptor in Injured Artery Induced by Cuff Placement in WT and Mas-Deficient Mice
We examined the changes in mRNA levels of ACE, ACE2, and Mas in the femoral artery 7 days after cuff placement, and the results are shown in Figure 4 . Both ACE2 and Mas mRNA levels were markedly decreased in the injured artery in WT mice, whereas ACE mRNA was not significantly changed, as previously reported (data not shown). 9 The changes in mRNA levels of ACE and ACE2 in the femoral artery of MasKO mice were not significantly different from those in WT mice. Expression of Mas mRNA was undetectable in the femoral artery of MasKO mice. We next examined the effects of administration of azilsartan or Ang-(1-7) on these mRNA levels. Expression of ACE mRNA in WT and MasKO mice did not change with these treatments. However, ACE2 mRNA level in the injured artery was higher in azilsartanand Ang-(1-7)-treated WT mice compared with untreated WT mice, whereas Mas mRNA level was not significantly changed by treatment with azilsartan or Ang-(1-7). In MasKO mice, ACE2 mRNA level in the injured artery was also higher in the azilsartan-and Ang-(1-7)-treated groups. AT 1 receptor mRNA level was not different among all groups. Expression of AT 2 receptor mRNA increased in the injured artery compared with the noninjured artery in both WT and MasKO mice. In addition, we observed that treatment with azilsartan or Ang-(1-7) increased AT 2 receptor mRNA level in the injured artery in both WT and MasKO mice compared with noninjured mice.
Possible Role of Ang-(1-7) in Vascular Remodeling via Angiotensin II Type 2 Receptor Stimulation
As shown in Figures 1 to 3 , administration of Ang-(1-7) did not effectively blunt neointimal formation, inflammation, or oxidative stress in MasKO mice compared with the effects in WT mice. These results support the possibility that Ang-(1-7) could activate the AT 2 receptor in this mouse model of vascular remodeling, as previously reported, 12 and that AT 2 receptor stimulation plays a critical role in the improvement of vascular injury. To further explore the involvement of the Ang-(1-7)/AT 2 receptor pathway in vascular remodeling after cuff placement, we also used AT 2 KO mice and examined the effect of Ang-(1-7) on neointimal formation ( Figure 5 ; Figure S6 ). The neointimal area after cuff placement was larger in AT 2 KO mice than in WT mice, as we previously reported. 16 Interestingly, we observed that the inhibitory effect of Ang-(1-7) on neointimal formation was less marked in AT 2 KO mice compared with WT mice (64.8% reduction in WT mice, 51.0% reduction in AT 2 KO mice). Mas mRNA level was not significantly changed in AT 2 KO mice compared with WT mice (data not shown). (Ang-(1-7) ) on superoxide anion production in injured artery induced by cuff placement in wild-type (WT) and Mas-knockout (MasKO) mice. Azil and Ang-(1-7) were administered as described in the Methods section. Artery samples were taken 7 days after cuff placement for measurement of superoxide production. In situ production of superoxide was detected with dihydroethidium as fluorescence intensity. 
Discussion
We demonstrated that neointimal formation, cell proliferation, inflammation, and oxidative stress in MasKO mice after cuff placement were enhanced compared with those in WT mice, that the effect of AT 1 receptor blockade by azilsartan was attenuated in MasKO mice, and that Ang-(1-7) treatment decreased neointimal formation after cuff placement even in MasKO mice; however, its effect on neointimal formation in MasKO mice was decreased compared with that in WT mice. We also observed that the effect of Ang-(1-7) on neointimal formation in AT 2 KO mice was less marked than that in WT mice. This experimental model actually reproduced the phenotype of small quantitative differences versus WT mice, with the neointimal area behaving in otherwise the same way to Ang-(1-7) in both WT and AT 2 KO mice. We speculate that the effects of Ang-(1-7) could be exerted simultaneously in concert with both Mas and AT 2 receptor stimulation. Accordingly, we proposed that blockade of the AT 1 receptor by azilsartan could enhance the activities of the ACE2/Ang-(1-7)/Mas axis and ACE2/Ang-(1-7)/AT 2 receptor axis, thereby inhibiting neointimal formation. ACE2 and its product Ang-(1-7) have been reported to exert antiatherosclerotic properties, including decrease in inflammation and cell proliferation. 17 For instance, chronic Ang-(1-7) infusion induced improvement of endothelial cell function and inhibited atherosclerotic lesion formation in apolipoprotein E-deficient mice. 18 Furthermore, a recent study demonstrated that long-term Ang-(1-7) treatment dose dependently inhibited early atherosclerotic lesion formation through vascular smooth muscle cell proliferation and migration in apolipoprotein E-deficient mice. 5 One important mechanism of vascular remodeling is via oxidative stress induced by the ACE/Ang II/AT 1 receptor axis, and the ACE2/Ang-(1-7)/Mas axis has also been reported to be involved in the regulation of oxidative stress. 19 For instance, it has been reported that MasKO mice from 2 different genetic backgrounds showed a reduction in superoxide dismutase and catalase activity, suggesting impaired antioxidant properties in these animals. 20 In addition, it is reported that the vasoprotective and atheroprotective effects of Ang-(1-7) are mediated by the restoration of nitric oxide bioavailability in apolipoprotein E-deficient mice. 4 In the present study, we demonstrated that neointimal formation after cuff placement was significantly greater in MasKO mice than in WT mice, with an increase in inflammation, oxidative stress, and cell proliferation. However, Ang-(1-7) treatment decreased neointimal formation, with attenuated inflammation, oxidative stress, and cell proliferation. These results suggest an important role of the ACE2/Ang-(1-7)/ Mas axis in vascular remodeling, including counteraction of inflammation and oxidative stress. Recently, Rompe et al 21 demonstrated that a direct AT 2 receptor stimulation reduces TNF-α-induced IL-6 expression by inhibition of nuclear factor-κB activity. Therefore, it is important to assess the nuclear factor-κB activity to understand in more detail the upstream of monocyte chemoattractant protein-1, TNF-α, and IL-1β in our experimental condition. Additional detailed investigation is necessary to investigate the role of ACE2/ Ang-(1-7)/Mas and possible Ang-(1-7)/AT 2 receptor axis in terms of preventing inflammation.
In our previous study using ACE2KO mice, it was shown that activation of the ACE2/Ang-(1-7)/Mas axis is at least partly involved in the beneficial effects of an ARB, olmesartan, on vascular remodeling. 9 It has also been suggested that AT 1 receptor stimulation regulated ACE2 and Ang-(1-7) expression in the aorta of spontaneously hypertensive rats. 7 Furthermore, it has been reported that an ARB, olmesartan, decreased neointimal formation and increased ACE2 immunostaining in the aorta after balloon injury in spontaneously hypertensive rats. 22 Koka et al 8 reported that Ang II downregulated ACE2 via the extracellular signal-regulated kinase/p38 mitogen-activated protein kinase pathway mediated by AT 1 receptor stimulation. In the present study, we also observed that the mRNA of ACE2 and Mas in the injured artery was markedly decreased in WT mice, and administration of azilsartan attenuated the decrease in ACE2 mRNA. In contrast, the inhibitory effects of azilsartan on vascular remodeling were attenuated in MasKO mice, despite restoration of the decreased ACE2 mRNA. Taking these findings together, AT 1 receptor blockade by ARBs seems to alter the balance between the ACE2/Ang-(1-7)-Mas axis and the ACE/Ang II/AT 1 receptor axis, with improvement in vascular remodeling. Consistently, an ARB, olmesaltan, has been reported to increase ACE2 expression in injured aorta and femoral artery.
9,22 Furthermore, we reported that AT 1 a receptor null mice showed an increase in ACE2 expression in the injured femoral artery after cuff placement. 9 In the present study, azilsartan also increased ACE2 expression in the injured femoral artery, in addition to an increase in AT 2 receptor expression. These results suggest that activation of the ACE2/Ang-(1-7)/Mas axis and Ang-(1-7)/AT 2 receptor axis is at least partly involved in the beneficial effects of ARBs.
Furthermore, we observed that the inhibitory effect of Ang-(1-7) on neointimal formation was less marked in AT 2 KO mice compared with WT mice. Recently, the Ang-(1-7)/AT 2 receptor axis has been highlighted as a (Ang-(1-7) ) on neointimal formation in injured artery induced by cuff placement in Ang II type 2 receptor knockout (AT 2 KO) mice. Ang-(1-7) was administered intraperitoneally at a dose of 0.5 mg/kg per day using an osmotic minipump at the same time as cuff placement. In the control group, saline was administered with an osmotic minipump. Artery samples were taken 14 days after cuff placement for measurement of neointimal area. Values are mean±SEM of 10 samples in each group. *P<0.05 vs wild-type (WT) control mice.
†P<0.05 vs AT 2 KO control mice.
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new pathway. 10 A previous report has demonstrated that Ang-(1-7) evoked a vasodepressor effect in conscious Wistar-Kyoto rats and spontaneously hypertensive rat in the presence of partial AT 1 receptor blockade, suggesting possible stimulation of the AT 2 receptor by Ang- (1-7) . 11 Another report has also demonstrated that chronic Ang-(1-7) treatment produced vasoprotective and atheroprotective effects in the apolipoprotein E-deficient mouse model of atherosclerosis as a result of increased nitric oxide bioavailability via both Mas and AT 2 receptors. 4 Our previous study showed that expression of the AT 2 receptor is upregulated in the injured femoral artery after cuff placement. 12 In addition, AT 2 receptor stimulation is known to be involved in the effects of ARBs on vascular remodeling. These results, including our previous results, suggest that the Ang-(1-7)/AT 2 receptor pathway is also involved in the inhibitory effects of ARBs on vascular remodeling. We observed that the Mas mRNA level was decreased in the injured artery of WT mice, whereas the expression of AT 2 receptor mRNA was increased in the injured femoral artery after cuff placement. 9, 12 We also observed the elevation of AT 2 receptor mRNA in the injured femoral artery in MasKO mice. Furthermore, administration of azilsartan or Ang-(1-7) further increased the expression of AT 2 receptor mRNA in the injured artery in WT and MasKO mice compared with that in control WT and MasKO mice. In addition, Ang-(1-7) treatment attenuated neointimal formation after cuff placement in MasKO mice, whereas this effect of Ang-(1-7) was less marked in MasKO mice than in WT mice. To confirm the involvement of the Ang-(1-7)/ AT 2 receptor axis in vascular remodeling after cuff placement, we also used AT 2 KO mice. Interestingly, we found that the effect of Ang-(1-7) on neointimal formation was less marked in AT 2 KO mice than in WT mice. These results support that blockade of the AT 1 receptor by azilsartan could enhance the activities of the ACE2/Ang-(1-7)/Mas axis and Ang-(1-7)/AT 2 receptor axis, thereby inhibiting neointimal formation. To confirm this hypothesis more clearly, we have been generating Mas/AT 2 receptor double knockout mice for the future experiment.
Perspectives
In summary, our results indicate possible involvement of both the ACE2/Ang-(1-7)/Mas axis and the Ang-(1-7)/AT 2 receptor pathways in the actions mediated by azilsartan in the context of vascular remodeling. Ang-(1-7) seemed to show counterregulation against vascular remodeling via the AT 2 receptor and Mas. In addition, blockade of the AT 1 receptor may enhance the activity of the Ang-(1-7)/AT 2 receptor axis, as well as the ACE2/Ang-(1-7)/Mas axis activity, and this mechanism may be involved in the beneficial effects of ARBs. 
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Generation of Mas1 knockout mice
MasKO mice (C57BL/6J background) at 10-11 weeks of age were used in the present study.
Targeted disruption of the Mas gene was as follows: Genomic clones containing fragments of the MAS1 gene were isolated from a C57BL/6 (RP23: 309H20) BAC clone. A 13.37Kb region used to construct the targeting vector was first subcloned and confirmed by sequencing. The Neo cassette replaced 4.83Kb of the gene including exon 9 and ~3Kb upstream of exon 9 including a repetitive sequence between 5.86Kb, the long homology arm located 5' to exon 9, and 2.69Kb, the short homology arm located 3' to exon 9. The and Mas-deficient (MasKO) mice. Azil and Ang-(1-7) were administered as described in "Methods". Artery samples were taken 7 days after cuff placement for measurement of superoxide production. In situ production of superoxide was detected with dihydroethidium, as described in "Methods". Representative images for detection of superoxide production in femoral artery with or without cuff placement are shown. MasKO control mice.
